Influences of CYP2D6*10 polymorphisms on the pharmacokinetics of iloperidone and its metabolites in Chinese patients with schizophrenia: a population pharmacokinetic analysis

Influences of CYP2D6*10 polymorphisms on the pharmacokinetics of iloperidone and its metabolites in Chinese patients with schizophrenia: a population pharmacokinetic analysis

<p>Aim: Iloperidone is an atypical antipsychotic drug that is mainly metabolized by CYP2D6, CYP3A4, and cytosolic enzymes. Previous studies show that extensive and poor metabolizers of CYP2D6 exhibit different plasma concentrations of iloperidone and its metabolites. The aim of this study was...

Full description

Bibliographic Details
Main Authors:	Pei, Q, Huang, L, Huang, J, Gu, J, Kuang, Y, Zuo, X, Ding, J, Tan, H, Guo, C, Liu, S, Yang, G
Format:	Journal article
Published:	Nature Publishing Group 2016

Similar Items

Effect of the Most Relevant CYP3A4 and CYP3A5 Polymorphisms on the Pharmacokinetic Parameters of 10 CYP3A Substrates
by: Miriam Saiz-Rodríguez, et al.
Published: (2020-04-01)

Sex-Specific Cannabidiol- and Iloperidone-Induced Neuronal Activity Changes in an In Vitro MAM Model System of Schizophrenia
by: Rachel-Karson Thériault, et al.
Published: (2021-05-01)

A Review of Population Pharmacokinetic Models of Posaconazole
by: Ding Q, et al.
Published: (2022-10-01)

Population Pharmacokinetics Of Repaglinide In Healthy Subjects And Genetic Polymorphisms Of Cyp3a4 And Cyp2c8
by: Abu Bakar, Ruzilawati
Published: (2008)

Evaluation of the relationship between polymorphisms in CYP2C19 and the single‐dose pharmacokinetics of omeprazole in healthy Chinese volunteers: A multicenter study
by: Shuang Zhou, et al.
Published: (2022-06-01)

Frequency of CYP3A5 Genetic Polymorphisms and Tacrolimus Pharmacokinetics in Pediatric Liver Transplantation
by: Jefferson Antonio Buendía, et al.
Published: (2020-09-01)

Physiologically Based Pharmacokinetic/Pharmacodynamic Modeling to Predict the Impact of CYP2C9 Genetic Polymorphisms, Co-Medication and Formulation on the Pharmacokinetics and Pharmacodynamics of Flurbiprofen
by: Ioannis Loisios-Konstantinidis, et al.
Published: (2020-11-01)

Population pharmacokinetics model for escitalopram in Chinese psychiatric patients: effect of CYP2C19 and age
by: Shujing Liu, et al.
Published: (2022-07-01)

Population pharmacokinetics of lenalidomide in Chinese patients with influence of genetic polymorphisms of ABCB1
by: Xiaoxiao Liang, et al.
Published: (2024-01-01)

Population Pharmacokinetics and Pharmacodynamics of Isoniazid and its Metabolite Acetylisoniazid in Chinese Population
by: Bing Chen, et al.
Published: (2022-07-01)

Population pharmacokinetics of Amisulpride in Chinese patients with schizophrenia with external validation: the impact of renal function
by: Anning Li, et al.
Published: (2023-09-01)

The impact of CYP3A4 and CYP3A5 polymorphisms on anastrozole's pharmacokinetics and pharmacodynamics in post-menopausal breast cancer patients
by: Abubakar, Murtala Bello
Published: (2017)

Pharmacokinetics and Main Metabolites of Anwulignan in Mice
by: Cong Chen, et al.
Published: (2022-07-01)

Highly Variable Pharmacokinetics of Tyramine in Humans and Polymorphisms in OCT1, CYP2D6, and MAO-A
by: Muhammad Rafehi, et al.
Published: (2019-10-01)

Impact of polymorphisms in CYP and UGT enzymes and ABC and SLCO1B1 transporters on the pharmacokinetics and safety of desvenlafaxine
by: Sofía Calleja, et al.
Published: (2023-02-01)

Physiologically based pharmacokinetic (PBPK) modeling of the role of CYP2D6 polymorphism for metabolic phenotyping with dextromethorphan
by: Jan Grzegorzewski, et al.
Published: (2022-10-01)

Population Pharmacokinetics of Hydroxychloroquine and 3 Metabolites in COVID-19 Patients and Pharmacokinetic/Pharmacodynamic Application
by: Jean Claude Alvarez, et al.
Published: (2022-02-01)

Pharmacokinetic, Pharmacokinetic/Pharmacodynamic, and Safety Investigations of Lefamulin in Healthy Chinese Subjects
by: Yingying Hu, et al.
Published: (2023-08-01)

Long-Term Treatment with Atypical Antipsychotic Iloperidone Modulates Cytochrome P450 2D (CYP2D) Expression and Activity in the Liver and Brain via Different Mechanisms
by: Przemysław J. Danek, et al.
Published: (2021-12-01)

Polymorphic Characterization, Pharmacokinetics, and Anti-Inflammatory Activity of Ginsenoside Compound K Polymorphs
by: Yun-Yan Kuang, et al.
Published: (2021-04-01)

Pharmacokinetic evaluation and metabolite characterization of the antimalarial piperaquine in the rat
by: Tarning, J, et al.
Published: (2007)

Influence of <i>CYP2C9</i> Genetic Polymorphisms on the Pharmacokinetics of Losartan and Its Active Metabolite E-3174: A Systematic Review and Meta-Analysis
by: Yoon-A Park, et al.
Published: (2021-06-01)

Single dose pharmacokinetics of proguanil and its metabolites in pregnancy.
by: Wangboonskul, J, et al.
Published: (1993)

Influence of <it>SLCO1B1 </it>and <it>CYP2C8 </it>gene polymorphisms on rosiglitazone pharmacokinetics in healthy volunteers
by: Aquilante Christina L, et al.
Published: (2008-09-01)

Population pharmacokinetics of voriconazole and the role of CYP2C19 genotype on treatment optimization in pediatric patients.
by: Lin Hu, et al.
Published: (2023-01-01)

Pharmacokinetics of the CYP3A4 and CYP2B6 Inducer Carbamazepine and Its Drug–Drug Interaction Potential: A Physiologically Based Pharmacokinetic Modeling Approach
by: Laura Maria Fuhr, et al.
Published: (2021-02-01)

Population pharmacokinetics of primaquine and its metabolites in African males
by: Chotsiri, P, et al.
Published: (2024)

Effects of the CYP3A inhibitors, voriconazole, itraconazole, and fluconazole on the pharmacokinetics of osimertinib in rats
by: Yutao Lou, et al.
Published: (2023-08-01)

Pharmacokinetics of Tamoxifen and Its Major Metabolites and the Effect of the African Ancestry Specific CYP2D6*17 Variant on the Formation of the Active Metabolite, Endoxifen
by: Comfort Ropafadzo Kanji, et al.
Published: (2023-01-01)

Population Pharmacokinetic Modelling for Nifedipine to Evaluate the Effect of Parathyroid Hormone on CYP3A in Patients with Chronic Kidney Disease
by: Fu C, et al.
Published: (2022-07-01)

Polymorphism of ORM1 is associated with the pharmacokinetics of telmisartan.
by: Wang-Qing Chen, et al.
Published: (2013-01-01)

Association between CYP2C19 and CYP2B6 phenotypes and the pharmacokinetics and safety of diazepam
by: Pablo Zubiaur, et al.
Published: (2022-11-01)

Open-Label, Phase I, Pharmacokinetic Studies in Healthy Chinese Subjects to Evaluate the Bioequivalence and Food Effect of a Novel Formulation of Abiraterone Acetate Tablets
by: Feng Z, et al.
Published: (2022-01-01)

Population Pharmacokinetics of Oxycodone and Metabolites in Patients with Cancer-Related Pain
by: Bram C. Agema, et al.
Published: (2021-06-01)

Population pharmacokinetic modeling of tribendimidine metabolites in Opisthorchis viverrini-infected adults
by: Vanobberghen, F, et al.
Published: (2016)

Physiologically Based Pharmacokinetic Modeling of Bupropion and Its Metabolites in a CYP2B6 Drug-Drug-Gene Interaction Network
by: Fatima Zahra Marok, et al.
Published: (2021-03-01)

Evaluation of Lidocaine and Metabolite Pharmacokinetics in Hyaluronic Acid Injection
by: Ju Hee Kim, et al.
Published: (2021-02-01)

Meropenem Pharmacokinetics and Target Attainment in Critically Ill Patients
by: Gan Y, et al.
Published: (2023-06-01)

Single Nucleotide Polymorphisms of CYP3A4 and CYP3A5 in Romanian Kidney Transplant Recipients: Effect on Tacrolimus Pharmacokinetics in a Single-Center Experience
by: Corina Andreea Rotarescu, et al.
Published: (2024-03-01)

The Effect of Chronic Iloperidone Treatment on Cytochrome P450 Expression and Activity in the Rat Liver: Involvement of Neuroendocrine Mechanisms
by: Przemysław J. Danek, et al.
Published: (2021-08-01)